Neomorph, Inc.

AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth

Another day and another deal in the molecular glue degrader (MGD) space has been inked, with Biogen the latest major company keen to explore the potential of protein degradation for previously undrugg